A Phase IIa Study of the Safety and Clinical Proof-of-Concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome

Trial Profile

A Phase IIa Study of the Safety and Clinical Proof-of-Concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2010

At a glance

  • Drugs Eprodisate (Primary)
  • Indications Metabolic syndrome; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 04 May 2010 The primary endpoint of this proof-of-concept trial was not met, according to a BELLUS Health media release. As a result, BELLUS have announced that they are discontinuing the development of NC 503 for type 2 diabetes mellitus.
    • 15 Apr 2008 Interim results are expected in late 2008 or early 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top